Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Palvella Therapeutics has received a consensus rating of "Moderate Buy" from thirteen rating firms, with one sell and eleven buy recommendations.
• The average twelve-month price target for Palvella Therapeutics stock is $75.50 based on recent analyst ratings.
• Palvella reported a loss of $0.86 per share in its latest earnings report, missing analysts' expectations of a $0.78 loss.

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $75.50.

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Wednesday. Chardan Capital lifted their target price on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the stock a "buy" rating in a report on Friday, September 26th. Raymond James Financial set a $54.00 target price on shares of Palvella Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Canaccord Genuity Group lifted their target price on shares of Palvella Therapeutics from $66.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Oppenheimer started coverage on shares of Palvella Therapeutics in a report on Tuesday, September 9th. They set an "outperform" rating and a $85.00 target price for the company.

Palvella Therapeutics Trading Down 0.3%

Shares of PVLA opened at $69.90 on Friday. The company has a market cap of $773.09 million, a price-to-earnings ratio of -5.78 and a beta of -0.13. Palvella Therapeutics has a 1-year low of $11.17 and a 1-year high of $76.43. The company's fifty day simple moving average is $54.75 and its 200 day simple moving average is $35.56.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.08). As a group, research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. boosted its position in shares of Palvella Therapeutics by 4.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company's stock valued at $16,283,000 after acquiring an additional 32,388 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Palvella Therapeutics in the second quarter valued at about $104,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics in the second quarter valued at about $85,000. Marshall Wace LLP boosted its position in shares of Palvella Therapeutics by 61.7% in the second quarter. Marshall Wace LLP now owns 49,077 shares of the company's stock valued at $1,106,000 after acquiring an additional 18,732 shares during the period. Finally, New York State Common Retirement Fund bought a new stake in shares of Palvella Therapeutics in the second quarter valued at about $110,000. Institutional investors own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.